Ocugen, Inc. to Present at BIO International Convention 2022
Research, News, and Market Data on Ocugen
MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that Michael Shine, Ocugen’s Senior Vice President, Commercial, will present at the 2022 BIO International Convention being held in San Diego, California, from June 13-16, 2022.
The Company presentation, which is scheduled for Monday, June 13, at 4:45 p.m. PT in Meeting Room 1 of the San Diego Convention Center, will focus on Ocugen’s robust clinical pipeline, including its COVID-19 vaccine candidate, COVAXIN™ (BBV152), its modifier gene therapy programs, and its new cell therapy program, NeoCart®.
About
Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.
Cautionary
Note on Forward-Looking Statements
This press release
contains forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, which are subject to risks and
uncertainties. We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words
that convey uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or results to
differ materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with the Securities
and Exchange Commission (“SEC”), including the risk factors described in the
section entitled “Risk Factors” in the quarterly and annual reports that we
file with the SEC. Any forward-looking statements that we make in this press
release speak only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements contained in
this press release whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact
Tiberend Strategic Advisors,
Inc.
Jonathan Nugent / Daniel Kontoh-Boateng (Investor)
jnugent@tiberend.com
dboateng@tiberend.com
Dave Schemelia (Media)
dschemelia@tiberend.com